GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Northwest Biotherapeutics Inc (OTCPK:NWBO) » Definitions » Operating Margin %

Northwest Biotherapeutics (Northwest Biotherapeutics) Operating Margin % : -3,402.70% (As of Dec. 2023)


View and export this data going back to 2001. Start your Free Trial

What is Northwest Biotherapeutics Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Northwest Biotherapeutics's Operating Income for the three months ended in Dec. 2023 was $-15.14 Mil. Northwest Biotherapeutics's Revenue for the three months ended in Dec. 2023 was $0.45 Mil. Therefore, Northwest Biotherapeutics's Operating Margin % for the quarter that ended in Dec. 2023 was -3,402.70%.

Good Sign:

Northwest Biotherapeutics Inc operating margin is expanding. Margin expansion is usually a good sign.

The historical rank and industry rank for Northwest Biotherapeutics's Operating Margin % or its related term are showing as below:

NWBO' s Operating Margin % Range Over the Past 10 Years
Min: -16273.21   Med: -6832.28   Max: -1160.95
Current: -2873.09


NWBO's Operating Margin % is ranked worse than
83.53% of 1026 companies
in the Biotechnology industry
Industry Median: -175.525 vs NWBO: -2873.09

Northwest Biotherapeutics's 5-Year Average Operating Margin % Growth Rate was 8.70% per year.

Northwest Biotherapeutics's Operating Income for the three months ended in Dec. 2023 was $-15.14 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-55.51 Mil.

Warning Sign:

Northwest Biotherapeutics Inc has never been profitable in the past 3 years. It lost money every year.


Northwest Biotherapeutics Operating Margin % Historical Data

The historical data trend for Northwest Biotherapeutics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Northwest Biotherapeutics Operating Margin % Chart

Northwest Biotherapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,160.95 -6,708.37 -5,243.98 -3,991.74 -2,873.08

Northwest Biotherapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3,044.89 -1,473.18 -6,754.73 -3,405.17 -3,402.70

Competitive Comparison of Northwest Biotherapeutics's Operating Margin %

For the Biotechnology subindustry, Northwest Biotherapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Northwest Biotherapeutics's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Northwest Biotherapeutics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Northwest Biotherapeutics's Operating Margin % falls into.



Northwest Biotherapeutics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Northwest Biotherapeutics's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-55.508 / 1.932
=-2,873.08 %

Northwest Biotherapeutics's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-15.142 / 0.445
=-3,402.70 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Northwest Biotherapeutics  (OTCPK:NWBO) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Northwest Biotherapeutics Operating Margin % Related Terms

Thank you for viewing the detailed overview of Northwest Biotherapeutics's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Northwest Biotherapeutics (Northwest Biotherapeutics) Business Description

Traded in Other Exchanges
Address
4800 Montgomery Lane, Suite 800, Bethesda, MD, USA, 20814
Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S. Food and Drug Administration.
Executives
Navid Malik director 1 CHOLMELEY PARK, HIGHGATE, LONDON X0 N6 5ET
Marnix L Bosch officer: Chief Technical Officer 22322 20TH AVENUE SE, STE 250, BOTHELL WA 98021
Alton L Boynton director, officer: Chief Scientific Officer 22322 20TH AVENUE SE, STE 150, BOTHELL WA 98021
Leslie J. Goldman officer: See Remarks C/O NORTHWEST BIOTHERAPEUTICS, INC., 4800 MONTGOMERY LANE, SUITE 800, NEW YORK NY 20814
Linda F Powers director, 10 percent owner, officer: President and CEO 7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814
Jerry J Jasinowski director C/O HARSCO CORP, P O BOX 8888, CAMP HILL PA 17001-8888
Jean M. Davis officer: See Remarks 4800 MONTGOMERY LANE, SUITE 800, BETHESDA MD 20814
Susan B Bayh director WELLPOINT, INC., 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Black Cofer director 4800 MONTGOMERY LANE, SUITE 800, BETHESDA MD 20814
Woodford Investment Management Llp 10 percent owner 27 OLD GLOUCESTER STREET, LONDON X0 WC1N 3AX
Cf Woodford Equity Income Fund 10 percent owner C/O WOODFORD INVESTMENT MANAGEMENT LTD, 9400 GARSINGTON ROAD, OXFORD X0 OX4 2HN
Cognate Bioservices, Inc. 10 percent owner 7513 CONNELLEY DRIVE, HANOVER MD 21076
Robert A Farmer director 10205 COLLINS AVE PENTHOUSE 6, MIAMI BEACH FL 33154
Toucan General Ii, Llc 10 percent owner 7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814
Hemphill Robert F Jr. 10 percent owner 7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814

Northwest Biotherapeutics (Northwest Biotherapeutics) Headlines

From GuruFocus